• Research, development, manufacture and sales of medical technology as well as pharmaceutical products and services with a focus on infusion-, nutrition- and pain therapies
• Approx. EUR 4.4 billion in revenue and 43,000 employees
• Hospital Care Division of B. Braun SE (EUR 8.5 billion in revenue, 65,000 employees)

Vice President Global Marketing and Sales Drugs and Nutrition

• Responsibility for securing the overall global divisional result of the Drugs & Nutrition business unit of the Hospital Care Division
• Personnel responsibility: 23 employees
• Revenue responsibility: EUR 1.2 billion

MAIN TASKS AND PROJECTS:

• Strategy / Marketing / Sales:
  • Leadership of business unit strategy development as well as the portfolio-, lifecycle- and project management of all intravenous (IV) drug and clinical nutrition (oral, enteral and parenteral) product lines
  • Optimization of all global production units and sales organizations in combination with the realignment of the product portfolio (incl. USA)
  • Conception and implementation of global omni-channel marketing measures, incl. success monitoring
  • Contribution to a uniform definition of global and local Marketing and Sales roles as part of a transformation
  • Development of a globally viable OTC umbrella brand concept, incl. expansion of B. Braun's B2C Corporate Identity in the area of enteral nutrition with a focus on Germany in 2023
• Product innovation:
  • Release of all R&D development contracts in the Drugs & Nutrition business unit
  • Preparation of business forecasts and decision documents for R&D and site investments
  • Analysis and interpretation of customer needs, incl. translation into new, profitable innovation projects
  • Co-development of health-economic and customer-relevant value-added claims in collaboration with Scientific Medical Affairs and Global Access Government Affairs
• Commercial optimization / digitization:
  • Introduction of virtual global physician training concepts and digital sales apps
  • Implementation of new methods and processes for gaining customer insights, expanding the digital innovation pipeline and reviewing the corresponding concept strength
  • Establishment of the basis and market access for IV drugs (injectables) in Brazil, Mexico, France and Germany to increase sales efficiency

• Expanded the IV Drug business share in USA and Latin America with revenue growth in 2022 of EUR 30 million (approx. 10% in the segment)
• Realized revenue growth of 12.5% (approx. 4 ? 5% above average market growth) in Clinical Nutrition
• Identified new life cycle projects as a basis for revenue growth of EUR >300 million in 2026/27 with significant margin improvement (increasing the consolidated margin by 3%)
• Product innovation:
  • Ensured new launches in 2022 including >20 launches of IV Drug focus products (particularly in the USA and Latin America)
  • ?Realized ?the global launch of APEX ® compounding solutions for patient specific parenteral nutrition in 2022

• Research, development, manufacture and sales of hygiene and disinfection products, especially for infection prevention
• EUR 200 million in revenue, 340 employees (Hamburg location)
• Subsidiary of PAUL HARTMANN AG (EUR 2.3 billion in revenue, 10,600 employees)

03/2020 ? 08/2021: Director Global Marketing, Member of the Management Board, ppa.

• Responsibility for the brand and portfolio strategy of the global Business Division Disinfection (BDD), incl. project management (BDD & SCM projects) as well as global Marketing (Hands and Surface Team)
• Personnel responsibility: 20 employees
• Revenue responsibility: EUR 200 million

MAIN TASKS AND PROJECTS:

• Steering of strategic and operational portfolio planning processes with R&D, Global Sales Development and the national subsidiaries
• Product innovation:
  • OTC brand extension and launch of Sterillium® Protect & Care 2018 in the DACH region, incl. expansion into 6 additional EU countries
  • Launch of Sterillium® foam, incl. establishment of two contract manufacturing organizations (CMOs) and launch projects in the USA within 24 months
  • Establishment of development cooperations for donors and dispensing devices, incl. global launches (focus on the USA and regions outside the EU)
• Digital health solutions:
• • Design and launch of the first digital solutions to increase hand hygiene compliance in 2019
  • Implementation of the first pilot of digital solutions in the field of hospital hygiene with external partners (start-ups) at 3 hospitals

NOTABLE ACHIEVEMENTS:

• Increased the EBIT margin during COVID by a factor of 4
• Achieved 5% of total revenue growth through new developments
• Sterillium®:
• • Regained market leadership in the German hospital market and defended the number 1 position in the German pharmacy market despite 800 new competitors
  • Once again recognized as "Brand of the Century"
  • Won the GOLD AWARD of COMPRIX 2019 in the category Multi-Channel Campaign

09/2017 ? 02/2020: Director Global Marketing and Sales, Member of the Management Board

• Responsibility for the brand and portfolio strategy of the global Business Division Disinfection (BDD), incl. project management (BDD & SCM projects), global Marketing (Hands and Surface Team) and global Sales
• P&L responsibility for the division's global direct business
• Personnel responsibility: 24 employees
• Revenue responsibility: EUR 200 million

OTHER MAIN TASKS AND PROJECTS NOT MENTIONED ABOVE:

• Management of the international sales expansion
• Evaluation of attractive sales channels and segments
• Internationalization, incl. new distribution contracts in the US, Poland and India
• Restructuring of the roles and responsibilities of the global Marketing and Sales teams
• Local value claim development for Sterillium® foam in the USA

NOTABLE ACHIEVEMENTS:

• Achieved the turnaround of the EBIT margin in the direct distributor business
• from 2017 to 2020 by +30% before COVID
• Expanded the USA business with a market share in the operating room and intensive care area by approx. 65% through the introduction of Sterillium® foam in hospitals and in the wards
• Realized the first milestones for market expansion in China
• Launched the first digital solutions in Infection Prevention

• Research, development, production and sales of drugs and devices to treat Parkinson's disease (Morbus Parkinson)
• EUR 70 million in revenue, 120 employees
• Subsidiary of STADA Arzneimittel AG (EUR 2.1 billion in revenue, 10,800 employees)

02/2016 ? 06/2017: Director Global Marketing & Strategic Alliances / Management Board

• Responsibility for:
  • Total revenue from distribution partners and STADA's own subsidiaries
  • The management of the global brand and portfolio strategy, customer management of cooperation partners as well as project management of product development
• Also Head of Clinical Research on an interim basis (8 months)
• Personnel responsibility: 11 employees
• Revenue responsibility: EUR 70 million

MAIN TASKS AND PROJECTS:

• Steering of strategic and operational portfolio planning processes with R&D and all life cycle development projects
• Evaluation of business development projects as well as elaboration of growth plans around innovation technologies with CMO partners in Italy and France
• Identification of in-licensing options and successful conclusion with Harvard University in the USA
• Implementation of the price premium strategy in the USA

NOTABLE ACHIEVEMENTS:

• Increased revenue by 40% from 2014 to 2017 by expanding a new market segment in Parkinson's therapy
• Completed and submitted the TOLEDO study to Lancet Neurology as the basis for an eight-fold increase in EBITDA by 2025 (market entry in the USA)
• Included another new development in the US JV contracts, incl. preparations for fast-track market access

08/2014 ? 01/2016: Regional Sales Director Europe / Management Board

• Responsibility for total revenue from distribution partners and STADA's own subsidiaries in Europe

MAIN TASKS, PROJECTS AND ACHIEVEMENTS:

• Organizational setup, assurance of market access and obtainment of reimbursement eligibility for APO-Go® (apomorphine) in Belgium and the Netherlands
• Negotiation and conclusion of new distribution contracts in 6 countries to increase revenue and profit
• Establishment of global partner meetings and development of a global digital sales training concept
• Switch of product registrations to Britannia Pharmaceutical

• Research, development, manufacture and sales of homeopathic combination remedies

07/2011 ? 05/2014:Head Global Marketing

• Responsibility for managing the global brand and portfolio strategy, internationalizing core products (USA, DACH, Eastern Europe and Latin America) and expanding OTC brands worldwide in the traditional pharmacy market
• Personnel responsibility: 15 employees
• Revenue responsibility: EUR 200 million

MAIN TASKS AND PROJECTS:

• Establishment of new market segments as well as the conception and implementation of strategic and operational portfolio planning processes with R&D and the national companies
• Restructuring and outsourcing of marketing service tasks
• Development of a US-specific brand portfolio, incl. market tests for final investment decision and board approval
• (Re-)positioning of the therapy system homotoxicology towards treatment concepts of bioregulatory medicine

NOTABLE ACHIEVEMENTS:

• Achieved the highest revenue in the company's history in 2014 with a simultaneous increase in profit
• Established Traumeel® as the company's first EUR 50 million brand by building up international sales channels and new marketing approaches
• Realized EUR >10 million in revenue with the core brand Neurexan® as a second global follower through internationalization measures

07/2010 ? 06/2011: Global Marketing Manager

• Responsibility for leading the global portfolio strategy of the homotoxicology therapy system, incl. global (re-)positioning and brand building
• Personnel responsibility: 2 employees

MAIN TASKS, PROJECTS AND ACHIEVEMENTS:

• Conversion of homotoxicology into a modern, scientifically based and comprehensible therapeutic approach
• Portfolio streamlining to increase profitability
• Implementation of global concept and acceptance testing for repositioning and brand development
• Logo and claim development

• Research and development of biotherapeutics and vaccines
• EUR 1.5 billion in revenue (Southern and Central Europe (SCE) region of the BU Established Products)
• HQ for the Generics business unit of the Pfizer Group

Director Business Operations ? BU Established Products (EP), South and Central Europe / Management Board 

• Responsibility for managing and ensuring all operational launch processes for the market launch of a broad, generic product portfolio with >3,500 articles in Europe
• Also responsible for regional business development (SCE), regional inlicensing negotiation and global management of the Fragmin® brand
• Personnel responsibility: 18 employees
• Revenue responsibility: EUR 1.5 billion

MAIN TASKS, PROJECTS AND ACHIEVEMENTS:

• Realization of the first generic portfolio launch in France and all other SCE countries with market shares of up to 8.6% in the first year (significantly above expectations of around 2% in the SCE region)
• Leadership of the integration of Wyeth into the SCE region with a significant profit increase by leveraging all available synergies
• Achievement of excellent personal and SCE team-wide survey scores (Gallup Employee Engagement) well above the company average (75th percentile)

• Research, development, manufacturing and sales of prescription drugs with a focus on rare diseases, internal medicine, inflammatory diseases, immunology, vaccines, oncology and anti-infectives
• USD 65 billion in revenue, 110,000 employees
• Publicly listed

• Regional headquarters for Eastern European markets
• EUR 1.8 billion in revenue, 3,500 employees

06/2007 ? 04/2009: Business Development Director Emerging Markets, Central Eastern Europe Region (CEER) / Management Board

• Responsibility for the strategic and operational functions Marketing, Pricing and Access, Business Intelligence and Sales Effectiveness in >27 countries of the CEER region
• Personnel responsibility: 8 employees
• Revenue responsibility: EUR 1.8 billion

MAIN TASKS, PROJECTS AND ACHIEVEMENTS:

• Achievement of growth of up to 4% over market 5 years in a row while increasing profitability by focusing on specialty products
• Development of an organizational go-to-market strategy with regard to new customer segments and sales channels (incl. creation of local structures)
• Field sales expansion in Russia, Romania and Poland
• Increase in sales efficiency targets and implementation of CRM systems

08/2006 ? 05/2007: Regional Marketing Manager Cardiovascular & Metabolic Areas, Central European Region

• Responsibility for the portfolio and brand management of the specialty therapy areas diabetes, hypotension, dyslipidemia, pulmonary hypertension and smoking cessation in 27 markets
• Revenue responsibility: EUR 800 million

MAIN TASKS, PROJECTS AND ACHIEVEMENTS:

• Realization of 22 new product launches within 12 months ? each exceeding their revenue targets
• Creation of marketing plans for core brands, such as Lipitor® and Champix®
• Development of a go-to-market model for the inhalable insulin Exubera® (product in pre-launch phase)

• German subsidiary of the Pfizer Group

04/2004 ? 05/2006: Regional Marketing Manager Neuroscience, Pain/Inflammation & Ophthalmology Therapy Areas, Central European Region

• Responsibility for the portfolio and brand management of the specialty therapy areas neurology, pain, epilepsy, rheumatic diseases and ophthalmology in 27 markets
• Revenue responsibility: EUR 200 million

MAIN TASKS AND PROJECTS:

• Realization of 34 new product launches within 18 months ? each exceeding their revenue targets two years in a row
• Creation of marketing plans for core brands, such as Lyrica®, Zeldox®, Zoloft®, Xalatan® and Macugen®
• Development and implementation of a go-to-market model and education plan for the treatment of macular degeneration

07/2001 ? 03/2004: Senior Product Manager Pharma CNS

• Responsibility for the portfolio and brand management of specialty therapy areas in the core market Germany (neurology, pain, epilepsy)
• Revenue responsibility: up to EUR 50 million

MAIN TASKS, PROJECTS AND ACHIEVEMENTS:

• Increase in revenue of EUR 3 million within one year through the direct marketing of Elcrit®, incl. best profitability margin of the Neuroscience business unit
• Realization of the first global launch of Zeldox® in GER (before launch in USA), incl. achievement of the highest market share in GER of >24% with Zoloft®
• Lead contributor to the global label expansion of Zoloft® to include post-traumatic stress disorder

10/2000 ? 06/2001

• Senior Product Manager CNS

01/2000 ? 09/2000

• Product Manager Pharma CNS

04/1999 ? 12/1999:

• Junior Product Manager Pharma CNS

04/1998 ? 03/1999:

• Traineeship ? Marketing Management